15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $73066 | -$25M | 23.1% | -19415.6% | 164.9% | -2613.1% | — | $3418 | $281435 |
| 2024 | $801273 | -$24M | -15.0% | -1235.6% | 127.5% | -861.0% | -$7M | $2M | $13789 |
| 2023 | $19M | -$21M | 29.5% | -81.1% | 374.7% | -212.2% | -$10M | $457656 | $379978 |
| 2022 | $18M | -$22M | 32.7% | -118.3% | -232.7% | -125.3% | -$14M | $3M | $4M |
| 2021 | $11M | -$29M | 34.6% | -257.0% | -327.4% | -177.3% | -$15M | $0 | $4M |
| 2020 | $2M | -$29M | 15.8% | -767.9% | 306.7% | -310.8% | -$21M | $1M | $380000 |
| 2019 | $20387 | -$5M | -1104.2% | -22009.4% | 52.6% | -848.4% | -$3M | $5216 | $42639 |
| 2018 | $1M | $68206 | 53.8% | 5.1% | -0.9% | 16.7% | -$13241 | $13739 | $938040 |
| 2017 | $895346 | -$147534 | 50.8% | -17.6% | 202.5% | -61.2% | -$75872 | $25305 | — |
| 2016 | — | -$48846 | — | — | -123.1% | -13.7% | -$26311 | $36223 | — |
| 2015 | — | $19153 | — | — | -1289.8% | 8.0% | -$13805 | $13566 | — |
| 2014 | — | -$30089 | — | — | 145.8% | -18.0% | -$29171 | $35825 | — |
| 2013 | — | -$30968 | — | — | 51.9% | -32.4% | — | $21321 | — |
| 2012 | — | -$12635 | — | — | 14.0% | -57.9% | — | — | — |
| 2011 | — | -$53096 | — | — | 57.3% | -229.7% | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$2M | — | — | 13.0% | -190.9% | — | — | $242702 |
| Mar '26 | $4224 | -$2M | 43.8% | -23176.4% | 13.2% | -277.5% | — | $857 | $381195 |
| Dec '25 | -$365206 | -$3M | -13.0% | 267.4% | 20.9% | -331.9% | — | $3418 | $281435 |
| Sep '25 | $0 | -$10M | — | — | -145.9% | -44.0% | — | $58130 | $265667 |
| Jun '25 | -$23406 | -$8M | 137.3% | 6417.1% | -97.4% | -38.2% | — | $52534 | $17213 |
| Mar '25 | $68606 | -$4M | 37.2% | -2417.1% | 18.2% | -145.5% | — | $2M | — |
| Dec '24 | -$3M | -$9M | 29.6% | 10.5% | 48.5% | -327.6% | — | $2M | $13789 |
| Sep '24 | $981859 | -$5M | 29.6% | -271.9% | 43.6% | -56.4% | — | $1M | — |
| Jun '24 | $1M | -$5M | 23.4% | -352.6% | 51.4% | -66.1% | — | $1M | — |
| Mar '24 | $2M | -$5M | 10.6% | -211.0% | 49.2% | -54.6% | -$1M | $810166 | $14757 |
| Dec '23 | $3M | -$6M | 27.3% | -122.3% | 106.9% | -60.6% | -$2M | $457656 | $379978 |
| Sep '23 | $5M | -$6M | 25.2% | -84.0% | 861.9% | -50.4% | -$2M | $408801 | $96121 |
| Jun '23 | $5M | -$6M | 34.2% | -81.3% | -141.3% | -42.7% | -$2M | $720861 | $903235 |
| Mar '23 | $6M | -$4M | 30.3% | -59.3% | -49.1% | -24.3% | -$4M | $2M | $2M |
| Dec '22 | $5M | -$5M | 31.5% | -99.6% | -51.4% | -27.7% | -$3M | $3M | $4M |
| Sep '22 | $5M | -$5M | 36.3% | -104.9% | -51.5% | -32.2% | -$4M | $248428 | $3M |
| Jun '22 | $4M | -$6M | 30.0% | -129.6% | -50.3% | -34.1% | -$2M | $357995 | $4M |
| Mar '22 | $4M | -$6M | 32.9% | -144.8% | -41.3% | -29.1% | -$5M | — | $8M |
| Dec '21 | $3M | — | 54.7% | -200.9% | 0.0% | 0.0% | -$3M | $0 | $4M |
| Sep '21 | $3M | -$12M | 29.0% | -427.0% | -122.3% | -62.5% | — | — | $8M |
How the market has priced EDVA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Endovia Health Sciences, Inc.'s revenue has declined 49.8% per year. These are computed facts, not advice.
As of FY2025, Endovia Health Sciences, Inc. reported $3418 of total debt against $281435 of cash; operating income covered interest expense -5.6×.
In FY2025, gross margin was 23.1%, operating margin -19415.6%, and net margin -34537.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.